Literature DB >> 744168

Competitive protein binding assay for 1,25-dihydroxy-vitamin D in human plasma.

S Dokoh, R Morita, M Fukunaga, I Yamamoto, K Torizuka.   

Abstract

A sensitive and simplified radioreceptor assay for 1, 25-dihydroxyvitamin D (1, 25-(OH)2D) in human plasma was described and applied to preliminary clinical studies. Tritium-labeled 1, 25-(OH)2D3 was produced by incubating chick kidney homogenate with tritium labeled 25-hydroxyvitamin D3 (25-OHD3). A cytosol receptor was obtained from rachitic chick intestine (Kd=5.3 X 10(-11) M). Lipids in 5 ml of heparinized human plasma were extracted with dichloromethane, and 1, 25-(OH)2D was isolated by a Sephadex LH-20 column followed by high pressure liquid column chromatography. Recovery of 1, 25-(OH)2D3 after the plasma extraction and chromatography ranged from 58 to 100%. The assay was sensitive to 5 pg/tube. Diluted plasma from a patient on a high dose of 1 alpha-OHD3 showed a dilution curve parallel to the standard curve. The cytosol receptor showed a cross reactivity to various vitamin D3 metabolites physiologically present in the circulation and it was thought to be essential to eliminate other vitamin D3 metabolites 1,25-(OH)2D from plasma samples by high pressure liquid chromatography. Plasma concentrations of 1, 25-(OH)2D were, in the case of most normal subjects, distributed from 7 to 33 pg/ml and the range of distribution became greater in relation to age, indicating that plasma values should be matched to age. Whereas markedly high values of 1, 25-(OH)2D in plasma were found in some cases of primary hyperparathyroidism with prominent bone resorption, relatively low values were seen in some patients with chronic renal failure, senile osteoporosis, osteomalacia and hypercalcemia due to bone metastasis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 744168     DOI: 10.1507/endocrj1954.25.431

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  7 in total

1.  Treatment of hypophosphataemic vitamin D-resistant rickets with massive doses of 1 alpha-hydroxy-vitamin D3 during childhood.

Authors:  Y Seino; T Shimotsuji; T Ishii; M Ishida; C Ikehara; K Yamaoka; H Yabuuchi; S Dokoh
Journal:  Arch Dis Child       Date:  1980-01       Impact factor: 3.791

2.  Differential diagnosis of hypoparathyroid disorders during childhood.

Authors:  M Ishida; Y Seino; T Simotsuji; T Ishii; K Yamaoka; T Harada; H yabuuchi; K Nishimura
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

3.  Calcium homeostasis in premature infants and treatment of early hypocalcaemia by 1,25-dihydroxycholecalciferol.

Authors:  C Y Lin; M Ishida
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

4.  Plasma 1,25-dihydroxyvitamin D concentrations in cords, newborns, infants, and children.

Authors:  Y Seino; T Shimotsuji; K Yamaoka; M Ishida; T Ishii; S Matsuda; C Ikehara; H Yabuuchi; S Dokoh
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

5.  Secondary hyperparathyroidism with 1,25-dihydroxyvitamin D deficiency and pseudohypoparathyroidism in childhood: relationship between plasma 1,25-dihydroxyvitamin D and parathyroid hormone levels and urinary cyclic AMP response to exogenous PTH.

Authors:  Y Seino; M Ishida; K Yamaoka; T Shimotsuji; T Ishii; H Yabuuchi; M Fukase; T Fujita
Journal:  Eur J Pediatr       Date:  1981-02       Impact factor: 3.183

6.  Influence of age on effects of endogenous 1,25-dihydroxyvitamin D on calcium absorption in normal women.

Authors:  P R Ebeling; A L Yergey; N E Vieira; M F Burritt; W M O'Fallon; R Kumar; B L Riggs
Journal:  Calcif Tissue Int       Date:  1994-11       Impact factor: 4.333

Review 7.  Vitamin D Metabolites: Analytical Challenges and Clinical Relevance.

Authors:  N Alonso; S Zelzer; G Eibinger; M Herrmann
Journal:  Calcif Tissue Int       Date:  2022-03-03       Impact factor: 4.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.